Trial · NCT00976352
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. | rAAV1-CMV-GAA Administration-cohort 1 | AAV1antibody Level -Screening | 40,031 | Standard Deviation 65324.18978 | mU/mL |
| Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. | rAAV1-CMV-GAA Administration-cohort 2 | AAV1antibody Level -Screening | 29,638 | Standard Deviation 12395.02473 | mU/mL |
| Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. | rAAV1-CMV-GAA Administration-cohort 1 | AAV1antibody Level - Day 365 | 5,509,882 | Standard Deviation 3051265.999 | mU/mL |
| Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. | rAAV1-CMV-GAA Administration-cohort 2 | AAV1antibody Level - Day 365 | 1,907,161 | Standard Deviation 3,189,557 | mU/mL |
| Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. | rAAV1-CMV-GAA Administration-cohort 1 | GAA Antibody level - Screening | 415.6666667 | Standard Deviation 61.71169527 | mU/mL |
| Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. | rAAV1-CMV-GAA Administration-cohort 2 | GAA Antibody level - Screening | 330.4 | Standard Deviation 271.1112318 | mU/mL |
| Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. | rAAV1-CMV-GAA Administration-cohort 1 | GAA Antibody level - Day 365 | 504.3333333 | Standard Deviation 63.88531391 | mU/mL |
| Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. | rAAV1-CMV-GAA Administration-cohort 2 | GAA Antibody level - Day 365 | 494.3333333 | Standard Deviation 371.6481311 | mU/mL |
| Maximal Inspiratory Pressure | rAAV1-CMV-GAA Administration-cohort 1 | Baseline | 6 | Full Range 2 to 22 | cm H2O |
| Maximal Inspiratory Pressure | rAAV1-CMV-GAA Administration-cohort 2 | Baseline | 61 | Full Range 3 to 85 | cm H2O |
| Maximal Inspiratory Pressure | rAAV1-CMV-GAA Administration-cohort 1 | Day 365 | 6 | Full Range 2 to 19 | cm H2O |
| Maximal Inspiratory Pressure | rAAV1-CMV-GAA Administration-cohort 2 | Day 365 | 56 | Full Range 3 to 75 | cm H2O |
| Evaluation of Ventilatory Performance Benefit of rAAV1-CMV-GAA Gene Transfer and Respiratory Muscle Strength Training (RMST) Compared to RMST Alone. | rAAV1-CMV-GAA Administration-cohort 1 | Screening | 6.85 | Full Range 1.6 to 26.1 | cm H2O |
| Evaluation of Ventilatory Performance Benefit of rAAV1-CMV-GAA Gene Transfer and Respiratory Muscle Strength Training (RMST) Compared to RMST Alone. | rAAV1-CMV-GAA Administration-cohort 2 | Screening | 60.8 | Full Range 1.9 to 82.6 | cm H2O |
| Evaluation of Ventilatory Performance Benefit of rAAV1-CMV-GAA Gene Transfer and Respiratory Muscle Strength Training (RMST) Compared to RMST Alone. | rAAV1-CMV-GAA Administration-cohort 1 | Baseline | 5.85 | Full Range 1.55 to 22.85 | cm H2O |
| Evaluation of Ventilatory Performance Benefit of rAAV1-CMV-GAA Gene Transfer and Respiratory Muscle Strength Training (RMST) Compared to RMST Alone. | rAAV1-CMV-GAA Administration-cohort 2 | Baseline | 60.8 | Full Range 2.65 to 84.85 | cm H2O |
| Evaluation of Ventilatory Performance Benefit of rAAV1-CMV-GAA Gene Transfer and Respiratory Muscle Strength Training (RMST) Compared to RMST Alone. | rAAV1-CMV-GAA Administration-cohort 1 | Day 365 | 5.7 | Full Range 1.65 to 19.1 | cm H2O |
| Evaluation of Ventilatory Performance Benefit of rAAV1-CMV-GAA Gene Transfer and Respiratory Muscle Strength Training (RMST) Compared to RMST Alone. | rAAV1-CMV-GAA Administration-cohort 2 | Day 365 | 55.6 | Full Range 2.9 to 75.1 | cm H2O |
| Evaluation of Tidal Volume Benefit of rAAV1-CMV-GAA Gene Transfer and Respiratory Muscle Strength Training, Compared to Respiratory Muscle Strength Training Alone. | rAAV1-CMV-GAA Administration-cohort 1 | Screening | 2.8 | Full Range 0.7 to 4.0 | mL/kg |
| Evaluation of Tidal Volume Benefit of rAAV1-CMV-GAA Gene Transfer and Respiratory Muscle Strength Training, Compared to Respiratory Muscle Strength Training Alone. | rAAV1-CMV-GAA Administration-cohort 2 | Screening | 7.9 | Full Range .14 to 8.7 | mL/kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00976352/results